Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow EyePoint Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for EyePoint Pharmaceuticals, Inc.

EYPT

EyePoint Pharmaceuticals, Inc.

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative sustained-release therapeutics for serious retinal diseases. Its pipeline includes lead candidates like DURAVYU, a bioerodible intravitreal treatment for wet AMD and DME, utilizing proprietary drug delivery technology. The company also markets approved products such as DEXYCU and licenses others internationally, leveraging its expertise in ophthalmic drug delivery and targeted therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from EyePoint Pharmaceuticals, Inc.

1
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports 97% Revenue Decline and $84.8 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports $231.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports 91% Revenue Decline and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports Revenue Decline and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports 109% Revenue Growth but Increases Net Loss to $45.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals Reports 6% Revenue Decline and $130.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
EyePoint Pharmaceuticals, Inc. Eyepoint Pharmaceuticals Reports 31% Revenue Decline, Widened Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments